V‐domain immunoglobulin suppressor of T‐cell activation and programmed death receptor 1 dual checkpoint blockade enhances antitumour immunity and survival in glioblastoma

Documenti analoghi

• Reprogramming tumour‐associated macrophages in breast cancer via si‐FOXM1‐loaded lipid nanoparticles enhances immune checkpoint inhibitor efficacy
  di: Yali Gao, et al.
  Pubblicazione: (2026)
• 7 I, a structurally modified sinomenine, exerts dual anti‐GBM effects by inhibiting glioblastoma proliferation and inducing necroptosis which further mediates lysosomal cell death
  di: Hong Yang, et al.
  Pubblicazione: (2025)
• Enhancing antitumour response to proteasome inhibitors with inhibitors of insulin‐degrading enzyme, a new molecular vulnerability in multiple myeloma
  di: Laetitia Lesire, et al.
  Pubblicazione: (2026)
• The impact of Foxp3 + regulatory T‐cells on CD8 + T‐cell dysfunction in tumour microenvironments and responses to immune checkpoint inhibitors
  di: Mikhaël Attias, et al.
  Pubblicazione: (2024)
• Clinical relevance of immune checkpoint inhibitors for the analgesic effect of opioids: A retrospective propensity score analysis
  di: Takahiro Sumimoto, et al.
  Pubblicazione: (2024)